Scheduled sale by CEO. sold 25,000 shares. Still owns 373,000. A non event. That is a pretty small percentage of his holdings in ISRG and part of his (or any) CEO typical plan to diversify periodically out of huge positions by founders.
Right now selling is technical and mostly shorts. Citron behind this as no new news out. Surveys go out to doctors for years not only with ISRG but all medical device makers. This is all about making news from nothing to create a quick short profit. Eventually shorts all buy back and stock squeezes higher. Who will get out and cover before the music stops to keep their profit?
Yes and if you look back you will see that these same people sold last year at this time, and the year before, and the year before, etc. This has nothing to do with any recent developments. This FDA survey is a non-issue as are these lawsuits. This is why neither ISRG, nor any of the analysts bothered to even bring it up on the call. More importantly there were no reserves set aside by this notoriously conservative management and the language regarding risks was largely unchanged from prior years in their recent SEC filings